Former Chief Scientific Officer · Tango Therapeutics, Inc. (TNGX)

Alan Huang

A named executive officer of Tango Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,770,905

Salary $350,615Stock awards $197,787

FY2022: $1,818,901

3rd of 4 named executive officers at Tango Therapeutics by FY2023 total.

4 named officers on file for Tango Therapeutics, FY2023

Alan Huang’s pay file — $29

  • 4 fiscal years of pay, line by line
  • TNGX’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tango Therapeutics’s whole pay program stands against its peers

  • Tango Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TNGX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Alan Huang’s full pay file as a PDF — free

More than this page: up to 10 years of Alan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Alan Huang compensation by year

Tango Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Tango Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023
Salary$373,806$394,793$425,385$350,615
Bonus$0$0$0$0
Stock awards$0$0$0$197,787
Option awards$70,566$1,649,121$1,197,000$807,012
Non-equity incentive$135,769$168,347$193,550$330,042
Pension and deferred compensation$0$0$0$0
All other$9,376$3,396$2,966$85,449
Total$589,517$2,215,657$1,818,901$1,770,905

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tango Therapeutics, Inc. DEF 14A filed April 29, 2024, accession 0000950170-24-049881, and prior-year filings.

How this page was built: the Tango Therapeutics, Inc. filed document, accession 0000950170-24-049881. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

$590K
$2.2M
$1.8M
$1.8M
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU6,339$62,756—
Option1,416—$1.65
Option38,036—$5.20
Option44,172—$3.50
Option14,154—$9.56
Option20,833—$9.22

Per the Outstanding Equity Awards at Fiscal Year-End table in Tango Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Tango Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Barbara WeberPresident, Chief Executive Officer and Director$3,391,059
Adam CrystalPresident of Research and Development$3,110,646
Alan Huang · this pageFormer Chief Scientific Officer$1,770,905
Daniella BeckmanChief Financial Officer$1,522,744

The full Tango Therapeutics compensation record

free company brief

This page is one person within Tango Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Tango Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tango Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alan Huang's compensation dossier · One-time report. No refunds.